Nivagen said it plans to use the proceeds for internal development and acquisition of additional generic and branded drugs to broaden its product portfolio.
The company is also exploring strategies to develop or acquire manufacturing facilities in the United States to help alleviate supply disruptions and accelerate time to market for its pipeline products.
Nivagen Pharmaceuticals is a specialty pharmaceuticals company engaged in the development and sale of difficult to formulate generic and branded prescription drugs for the North American market.
Nivagen is building a portfolio of high-quality, sustainable drug products by developing, acquiring, and in-licensing unique formulations to serve the needs of its customers.
Telegraph Hill Partners, founded in 2001 and based in San Francisco, CA, invests in commercial stage life science, medical technology and healthcare companies.
CivicaScript launches droxidopa for symptomatic neurogenic orthostatic hypotension
Padagis' Naloxone HCl Nasal Spray 4 mg obtains extended shelf-life of 36 months
ANI Pharmaceuticals announces US launch of Nitazoxanide Tablets
Newbury Pharmaceuticals secures approval for Macitentan in Denmark
Mallinckrodt and Endo to merge in USD6.7bn deal to create pharmaceutical leader
Genomma Lab Internacional announces quarterly dividend
Aveva Drug Delivery systems introduces generic Fentanyl Transdermal Patch in US
Independent Pharmacy Cooperative signs cooperation agreement with Legacy Pharmacy Group
ILIKOS Consulting partners with Jordan Center for Pharmaceutical Research
Axsome Therapeutics settles patent litigation with Teva over AUVELITY
Breckenridge Pharmaceutical's Everolimus Tablets for Oral Suspension receive US FDA approval
Newbury Pharmaceuticals secures generic approval for pomalidomide in Denmark
Newbury Pharmaceuticals secures generic approval for Bosutinib in Norway
Guangzhou Fermion Technology partners with Simcere Pharmaceutical